If semaglutide is not working for you, the most common reasons are being still in the titration phase, hidden calories overriding appetite suppression, or being a non-responder. About 14 percent of STEP-1 trial participants did not reach 5 percent body weight loss at any point in 68 weeks on Wegovy — meaning a meaningful minority of patients do not respond to semaglutide even with full adherence. Below is a practical troubleshooting framework before declaring the drug a failure for you.
First Question: Are You at Maintenance Dose?
The standard Wegovy titration is 16 weeks long. The starting doses (0.25, 0.5 mg) produce minimal weight loss because they’re designed to acclimate your body, not to produce maximum effect. If you’re 4 weeks in on 0.25 mg and not losing weight, that’s expected — not a treatment failure.
Significant weight loss typically appears in the 1.0-2.4 mg dose range (weeks 9-17+). Average trial participants lost 6 percent body weight by week 12 and 15 percent by week 68 at the 2.4 mg maintenance dose.
If you’re still titrating, give the drug time to reach the maintenance dose. If your prescriber paused your titration due to side effects, discuss whether resuming or finding an alternative makes sense.
Second Question: Are You Eating More Than You Think?
Semaglutide reduces hunger and appetite. It doesn’t override calories — if you consume calories your body doesn’t need, you won’t lose weight regardless of GLP-1 activity.
Common hidden calorie sources:
- Sugary drinks: 200-400 calories per soda, juice, or sweetened coffee drink — easily missed
- Alcohol: 100-200 calories per drink; reduces inhibition around food
- Cooking oils and fats: tablespoon of oil = ~120 calories; easily underestimated
- Snacking despite no hunger: habit eating rather than physiological hunger
- Large portions of healthy food: nuts, avocado, olive oil are nutritious but calorically dense
- Tasting while cooking, finishing kids’ plates: uncounted but real calories
Track everything you eat and drink for one week (use a food tracking app). The result often surprises people. If you’re consuming more than your body needs, semaglutide cannot overcome it.
Third Question: Are You Losing Muscle Instead of Fat?
Rapid weight loss without adequate protein and resistance training causes substantial muscle loss alongside fat loss. Muscle loss lowers your resting metabolic rate, making continued weight loss harder. The scale moves but your body composition gets worse.
Recommendations during semaglutide treatment:
- Aim for 0.8-1.2 g protein per kg body weight per day (higher end for active individuals)
- Strength training 2-3 times per week (full-body or split routine)
- Maintain or increase daily steps and activity
- Monitor body composition (not just weight) — DEXA scans or body fat measurements help
Fourth Question: What About Sleep, Stress, and Hormones?
Poor sleep increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), working against semaglutide’s appetite-reducing effects. Chronic stress raises cortisol, which promotes belly fat storage and increases hunger.
Underlying conditions that can blunt weight loss:
- Hypothyroidism (slows metabolism)
- PCOS (insulin resistance)
- Cushing’s syndrome (rare but possible)
- Certain medications (steroids, some antidepressants, some antipsychotics)
- Menopause (hormonal changes affect body composition)
If you suspect any of these, get bloodwork (TSH, fasting insulin, cortisol if symptoms warrant) to rule them in or out.
Fifth Question: Are You a Non-Responder?
About 14 percent of STEP-1 trial participants did not reach 5 percent body weight loss at any point in 68 weeks on Wegovy. This isn’t well-explained — possible factors include genetics, baseline metabolic profile, gut microbiome differences, or unmeasured behavioral factors. Some people simply do not respond to semaglutide for reasons not yet characterized.
If you’ve been at the 2.4 mg maintenance dose for 12-16 weeks with full adherence and no meaningful weight loss, you may be a non-responder. The next step is often switching to tirzepatide, which works through an additional receptor pathway (GIP) and produces more average weight loss in head-to-head trials. About 65 percent of patients who responded poorly to semaglutide responded better to tirzepatide in clinical observations.
The Plateau Problem
Many people lose weight rapidly in the first 6 months on semaglutide, then plateau. This is normal and reflects metabolic adaptation — your body’s resting metabolic rate decreases as you lose weight, so the calorie deficit needed to continue losing shrinks.
Strategies for breaking a plateau:
- Reassess your calorie intake (your maintenance calories are now lower than they were at your starting weight)
- Add or intensify strength training (preserves and builds metabolically active muscle)
- Increase protein (supports muscle maintenance)
- Consider whether dose increase is appropriate (within FDA-approved range)
- Discuss switching to tirzepatide with your prescriber
- Accept that some weight loss plateau is normal and not necessarily a failure
When to Talk to Your Prescriber
Contact your prescriber if:
- You’ve been at the maximum maintenance dose for 12-16 weeks without meaningful weight loss
- You’re experiencing significant side effects without weight-loss benefit
- You’ve audited diet, sleep, and exercise and still see no progress
- You suspect an underlying condition is interfering
- Your insurance situation is changing and you need to plan ahead
A productive appointment includes your weight log, food diary (1-2 weeks), current dose history, and any specific concerns or questions.
The Bottom Line
Semaglutide not working often means still being in titration, hidden calorie sources, muscle loss masking fat loss potential, sleep/stress factors, or being a non-responder. Audit your calories, protect muscle with protein and strength training, address sleep and stress, and rule out underlying conditions. About 14 percent of trial participants did not reach 5 percent weight loss; if you’ve adequately tried the drug at maintenance dose, switching to tirzepatide is a reasonable next step. Consult your prescriber to discuss your specific situation. For more on treatment options, see our hub.
